

Granulocyte-Macrophage Colony-stimulating Factor

Sensitive and Receptor-mediated Regulation by 1,25-Dihydroxyvitamin D₃ in Normal Human Peripheral Blood Lymphocytes

A. Tobler, J. Gasson, H. Reichel,* A. W. Norman,* and H. P. Koeffler

Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles Medical Center, Los Angeles, California 90024; and *Department of Biochemistry, University of California, Riverside, California 92521

Abstract

We show that 1,25-dihydroxyvitamin D₃ (1,25[OH]₂D₃), the most hormonally active metabolite of vitamin D₃, modulates sensitively and specifically both the protein and messenger RNA accumulation of the multilineage growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF). The regulation of GM-CSF expression is seen in both normal human mitogen-activated T lymphocytes and T lymphocytes from a line (S-LB1) transformed with human T cell lymphotropic virus 1 (HTLV-1). In contrast, cells from a HTLV-1 transformed T lymphocyte line (Ab-VDR) established from a patient with vitamin D-resistant rickets type II with undetectable 1,25(OH)₂D₃ cellular receptors are resistant to the action of 1,25(OH)₂D₃. Inhibition of GM-CSF expression by 1,25(OH)₂D₃ can occur independently of interleukin 2 regulation and is probably mediated through cellular 1,25(OH)₂D₃ receptors. We conclude that 1,25(OH)₂D₃ may be important in the physiology of hematopoiesis.

Introduction

Evidence is accumulating that the hormonally active metabolite of vitamin D₃, 1,25-dihydroxyvitamin D₃ (1,25[OH]₂D₃),¹ might play an important role as an immunohematopoietic regulatory hormone (reviewed in references 1, 2). Specific 1,25(OH)₂D₃ receptors are present in normal human mitogen-activated and malignant T and B lymphocytes and myeloid cells (3, 4). 1,25(OH)₂D₃ enhances the in vitro differentiation of normal and leukemic myeloid stem cells towards macrophages (5-7). 1,25(OH)₂D₃ inhibits proliferation and suppresses interleukin 2 (IL-2) synthesis of mitogen-activated T lymphocytes (8-11). Human macrophages activated by γ -interferon synthesize 1,25(OH)₂D₃ (12, 13).

Address reprint requests to Dr. A. Tobler, UCLA School of Medicine, Division of Hematology/Oncology, 11-240 Factor Building, Los Angeles, CA 90024.

Received for publication 29 July 1986 and in revised form 23 December 1986.

1. *Abbreviations used in this paper:* 1,25(OH)₂D₃, 1,25-dihydroxyvitamin D₃; CM, conditioned medium; ED₅₀, dose effective in achieving half-maximal response; GM-CFC, granulocyte-macrophage colony-forming cells; GM-CSF, granulocyte-macrophage colony-stimulating factor; HTLV-1, human T cell lymphotropic virus 1; IL-2, interleukin 2; PBL, normal human peripheral blood lymphocytes; PHA, phytohemagglutinin.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/87/06/1700/06 \$1.00

Volume 79, June 1987, 1700-1705

Survival, proliferation, and differentiation of hematopoietic cells are dependent on colony-stimulating factors (CSF). The granulocyte-macrophage CSF (GM-CSF), which is synthesized by activated T lymphocytes, has been cloned (14, 15). Recombinant and natural GM-CSF possess multilineage colony-stimulating activity (16, 17) and also enhances mature cell function of neutrophils and eosinophils (18, 19). We report here that 1,25(OH)₂D₃ sensitively and specifically inhibits the expression of GM-CSF in T lymphocytes.

Methods

Compounds. The vitamin D₃ metabolites (1,25[OH]₂D₃, 1,24,25-[OH]₂D₃, and 25[OH]D₃) were a generous gift from Dr. M. Uskokovic, Hoffmann-La Roche, Inc., Nutley, NJ. The compounds were dissolved in 100% ethanol to a stock concentration of 1×10^{-3} M and stored at -20°C. The various concentrations (10^{-11} - 10^{-7} M) were obtained by diluting the stock solutions in phosphate-buffered saline (PBS). The concentration of ethanol did not exceed 0.1%. Recombinant human IL-2 was generously provided by Jürgen Besemer (Sandoz Ltd., Vienna, Austria). Phytohemagglutinin (PHA) (Wellcome Diagnostics, Dartford, England) was used in a final concentration of 0.5%.

Cells and liquid culture assay. The human cell lines S-LB1 (20), Ab-VDR (H. P. Koeffler and A. W. Norman, unpublished observations), HL-60 (21), and KG-1 (22) were maintained in suspension culture T flask (Miles Laboratories Inc., Naperville, IL), containing alpha medium (Flow Laboratories, Inc., Rockville, MD) and 10% fetal calf serum (FCS) (Irvine Scientific, Santa Ana, CA) in a humidified atmosphere of 7% CO₂. The medium was changed two times a week.

Human peripheral blood lymphocytes (PBL) and human bone marrow cells were obtained from normal volunteers and isolated by Ficoll-Hypaque density gradient (1.077 g/ml) (Sigma Chemical Co., St. Louis, MO). Monocytes were removed from PBL by their ability to adhere to plastic for 6 h. The PBL and the human HTLV-1 immortalized T lymphocyte cell lines (S-LB1, Ab-VDR) were cultured for 2 d at 1×10^6 cells/ml in alpha medium-supplemented with 10% FCS in the presence of the various additives (vitamin D₃ compounds, PHA, IL-2) at 37°C in a humidified atmosphere of 7% CO₂. The conditioned media (CM) were stored at 4°C. Cell viability was not affected in the various experimental protocols, as determined by trypan blue exclusion.

Colony formation assay by two-layer agar techniques. The underlayer was plated in 1-ml portions in 35-mm petri dishes (Miles Laboratories Inc.) containing 0.5% agar, alpha medium, 16% FCS and CM from PBL as a source of CSF. CM obtained from the human T lymphocyte Mo cell line was used for control purpose at a final concentration of 1.5% (23). The overlayer contained the GM-CSF responder cells (bone marrow, KG-1), alpha medium, 16% FCS, penicillin, streptomycin, and 0.3% agar. The culture dishes were incubated at 37°C in a humidified atmosphere with 7% CO₂ for 10-13 d. Colonies (> 40 cells) were counted using an inverted microscope.

Complementary DNA (cDNA) probes, Northern blot technique. The IL-2 cDNA was a generous gift from S. Clarke, Genetics Institute, Boston, MA (24). The IL-2 receptor cDNA was kindly provided by T. Nikaido (25). The IL-2 and the IL-2 receptor probes were [³²P]-labeled by the

random priming method as described (26). The GM-CSF probes were [³²P]-labeled by nick translation (27).

For cytoplasmic RNA, freshly harvested cells were suspended in hypotonic buffer (10 mM Tris-HCl [pH 7.4], 1 mM KCl, 3 mM MgCl₂) and were lysed with Nonidet P-40 (0.3%). Nuclei were removed by centrifugation. Cytoplasmic RNA was extracted by the phenol/chloroform method as essentially described (28) and quantified by absorbance at 260 nm. Samples were denatured at 65°C for 10 min, size-separated by an agarose formaldehyde gel (1% agarose [Bethesda Research Laboratories, Gaithersburg, MD], 50 mM Na acetate, 10 mM Na₂ EDTA, 200 mM MOPS, and 2.2 M formaldehyde), and transferred to a nylon membrane filter (ICN Biomedicals Inc., Irvine, CA). Filters were dried, baked at 80°C in vacuo for 2 h, and then prehybridized for 16–24 h. Hybridizations with [³²P]-labeled cDNA (1 × 10⁶ cpm/ml) were performed at 42°C for 16–24 h in a solution containing 50% (vol/vol) formamide, 2× SSC (1× SSC is 150 mM NaCl, 15 mM sodium citrate), 5× Denhardt's (1× Denhardt's is 0.02% Ficoll/0.02% polyvinylpyrrolidone/0.02% bovine serum albumin), 0.1% sodium dodecyl sulfate (SDS), 1 mM EDTA, 10% (vol/vol) dextran sulfate (500,000 mol wt) (Sigma Chemical Co.), and 100 μg/ml salmon sperm DNA (Sigma Chemical Co.). Filters were washed to a stringency of 0.1× SSC, 1% SDS at 65°C and exposed for 24–48 h at -70°C to XAR-5 film (Eastman Kodak Co., Rochester, NY).

Measurement of [¹⁴C]uridine incorporation. S-LB1 cells (1 × 10⁶/ml) were exposed in 24-well plates (Miles Laboratories Inc.) in quadruplicates for various durations (0, 6, 48 h) to 1,25(OH)₂D₃ (10⁻⁸ M). Cells were pulsed with 0.5 μCi of [¹⁴C]uridine (New England Nuclear, Boston, MA) for 2 h at 37°C, washed twice in PBS, precipitated in 5% trichloroacetic acid (TCA) for 10 min, washed twice in 5% TCA, and heated at 80°C for 60 min. 200 μl of each sample was counted by liquid scintillation.

Measurement of [³H]thymidine incorporation. PBL (1 × 10⁶/ml) were cultured in the presence of 0.5% PHA and 1,25(OH)₂D₃ (10⁻⁷ M) in equal volumes (100 μl) in triplicates in 96-well plates (Corning Glass Works, Corning, NY). After 48 h, cells were pulsed with 1 μCi of [³H]thymidine (ICN Biomedicals Inc.) for 5 h at 37°C and harvested into glass filter fiber with a Mash II cell harvester (Skatron, Inc., Sterling, VA) and counted by liquid scintillation.

Results

Modulation of GM-CSF protein levels by 1,25(OH)₂D₃ and influence of IL-2 on GM-CSF expression in peripheral blood lymphocytes: dose response. The PBL (1 × 10⁶/ml) were cultured in the presence of increasing concentrations of 1,25(OH)₂D₃ (10⁻¹¹–10⁻⁷ M) and PHA (0.5%). After 2 d, CSF activity of the CM was assayed for stimulation of clonal growth of both normal human granulocyte-macrophage colony-forming cells (GM-CFC) and the human myeloblastic leukemic cell line KG-1 (Fig. 1 A). Clonal growth of both GM-CFC and KG-1 cells is dependent on CSF (22). We found that 1,25(OH)₂D₃ decreased levels of GM-CSF protein in a dose-dependent fashion with a 50% reduction of CSF activity (ED₅₀) at ~ 5 × 10⁻¹⁰ M 1,25(OH)₂D₃ when tested on clonal growth of GM-CFC and KG-1 cells. Control dishes containing no 1,25(OH)₂D₃ formed 127 ± 8 (±SD) GM-CFC and 62 ± 10 (±SD) KG-1 colonies. No difference in colony formation could be observed when 1,25(OH)₂D₃ (10⁻⁸ M) was added directly to the culture dishes containing CM of PHA-activated PBL compared with the control dishes containing CM of PHA-stimulated PBL only.

Prior studies showed that 1,25(OH)₂D₃ decreased proliferation and IL-2 synthesis by PBL (8–11). We examined, therefore, whether IL-2 might affect the modulation of GM-CSF production by 1,25(OH)₂D₃ in lymphocytes (Fig. 1 A). The PBL were cultured for 48 h in the presence of a high concentration of recombinant human IL-2 (200 ng/ml/10⁶ cells), 1,25(OH)₂D₃




Figure 1. Modulation of GM-CSF expression by 1,25(OH)₂D₃ in PBL. Dose-response studies (A–C): (A) Regulation of GM-CSF protein production. PBL were cultured for 48 h in the presence of PHA and 1,25(OH)₂D₃. GM-CSF activity of the CM was tested by measuring clonal growth of both a normal human GM-CFC (○) and a leukemic myeloblastic cell line KG-1 (●). In a parallel series of experiments, recombinant IL-2 (200 ng/ml) was added to the cultures and the CM was assayed on GM-CFC (●). The IL-2 alone had no effect on clonal growth. (B and C) Regulation of GM-CSF mRNA levels (Northern blots). PBL were incubated for 48 hours with PHA and 1,25(OH)₂D₃. When probed with GM-CSF cDNA, a single band was detected at 0.9 kb consistent with the known length of GM-CSF mRNA (B). The same Northern blot was reprobed with IL-2 receptor cDNA, as a control (C). Two bands were observed at 1.4 and 3.5 kb consistent with IL-2 receptor mRNA. Time-response studies (D and E): (D) Regulation of GM-CSF protein production. PBL were exposed to PHA and for various durations (12–48 h) to 1,25(OH)₂D₃ (10⁻⁸ M). All time points were harvested after 48 h. GM-CSF activity was assayed on GM-CFC. (E) Regulation of GM-CSF mRNA levels (Northern blot). PHA-activated PBL were cultured for various durations (6–48 h) with 1,25(OH)₂D₃ (10⁻⁸ M). PBL at all time points were harvested after 48 h. Each experiment in A and D represents the mean ± SD from three independent experiments with PBL from three different donors. RNA was extracted as described in Methods. Each lane in B, C, and E contains 30 μg cytoplasmic RNA. Results are expressed as a percent reduction of mRNA accumulation by 1,25(OH)₂D₃ as compared with the untreated control sample not exposed to 1,25(OH)₂D₃ (determined by densitometry on different exposures of preflashed autoradiograms).

(10⁻¹¹–10⁻⁷ M) and PHA (0.5%); the CM was assayed for stimulation of GM-CFC. We found that the addition of IL-2 to the cultures slightly blunted but did not reverse the inhibitory action of 1,25(OH)₂D₃ on GM-CSF protein activity. The IL-2 alone

had no effect on clonal growth of GM-CFC. CM from control cultures (PHA 0.5%, no IL-2, no $1,25(\text{OH})_2\text{D}_3$) stimulated a mean 243 ± 8 (\pm SD) GM-CFC per 2×10^5 mononuclear bone marrow cells.

Modulation of GM-CSF mRNA levels by $1,25(\text{OH})_2\text{D}_3$ in PBL: dose response. The modulation of GM-CSF mRNA levels of PBL cultured with various concentrations of $1,25(\text{OH})_2\text{D}_3$ was determined by Northern blot analysis (Fig. 1 B). The PBL were pooled from seven different donors, exposed for 2 d to increasing concentrations of $1,25(\text{OH})_2\text{D}_3$ (10^{-11} – 10^{-8} M) and PHA (0.5%) and the mRNA was extracted. A single band of hybridization was detected at 0.9 kb, which is consistent with GM-CSF mRNA (14, 15). The $1,25(\text{OH})_2\text{D}_3$ reduced mRNA accumulation in a dose-dependent manner with an ED_{50} of $\sim 5 \times 10^{-11}$ M as determined by densitometry reading. The same Northern blot was washed and reprobbed with a human cDNA for the IL-2 receptor gene to exclude a nonspecific degradation of mRNA (Fig. 1 C). Two classes of IL-2 receptor mRNA could be observed at 1.4 and 3.5 kb, which is in accordance with previously reported data (25). No significant change of IL-2 receptor mRNA (1.4-kb band) could be detected.

Modulation of GM-CSF protein and mRNA levels by $1,25(\text{OH})_2\text{D}_3$ in PBL: time response. We examined whether $1,25(\text{OH})_2\text{D}_3$ might be able to down-regulate protein and mRNA levels of GM-CSF in PBL already activated by PHA (Fig. 1, D and E). For all time points, the PBL were exposed for 48 h to PHA (0.5%). The $1,25(\text{OH})_2\text{D}_3$ (10^{-8} M) was added to the cultures at times 0, 24, 36 h for the protein studies, and 0, 24, 42 h for the mRNA studies. Control samples were stimulated by PHA alone. We found that a 12-h exposure to $1,25(\text{OH})_2\text{D}_3$ inhibited GM-CSF protein production by $\sim 50\%$ in PBL previously activated with PHA for 36 h (Fig. 1 D); and a 6-h exposure to $1,25(\text{OH})_2\text{D}_3$ was sufficient to reduce mRNA levels of GM-CSF by $\sim 50\%$ in PBL previously activated for 42 h (Fig. 1 E).

Regulation of GM-CSF mRNA levels by $1,25(\text{OH})_2\text{D}_3$ in a HTLV-1 immortalized T lymphocyte line (S-LB1). We performed a parallel series of experiments using a human T lymphocyte line (S-LB1) established by infection of normal human T lymphocytes with HTLV-1 (20). These cells constitutively synthesize GM-CSF and express high levels of IL-2 receptors (29, 30). S-LB1 cells were exposed for 48 h to increasing concentrations of $1,25(\text{OH})_2\text{D}_3$ (10^{-11} – 10^{-7} M) (Figs. 2 A). The $1,25(\text{OH})_2\text{D}_3$ decreased GM-CSF mRNA levels in a dose-dependent fashion as shown on the Northern blot, and a 50% reduction of mRNA occurred at $\sim 2.5 \times 10^{-11}$ M. Time-response experiments showed that a 50% decrease of GM-CSF mRNA accumulation occurred within 6 h of exposure of S-LB1 cells to $1,25(\text{OH})_2\text{D}_3$ (10^{-8} M) (Fig. 2 B). For control purpose, the same samples were reprobbed with IL-2 receptor cDNA (Fig. 2 C). Only a slight change of the IL-2 receptor mRNA levels (1.4-kb band) could be detected when S-LB1 cells were exposed to $1,25(\text{OH})_2\text{D}_3$ (10^{-8} M), as compared to the marked decrease of GM-CSF mRNA levels.

Receptor-mediated modulation of GM-CSF expression by vitamin D_3 seco-steroids. We first studied the ability of other metabolites of vitamin D_3 to regulate the accumulation of GM-CSF mRNA by S-LB1 cells (Fig. 3 A). The S-LB1 cells were cultured for 48 h with different vitamin D_3 metabolites (10^{-8} M). The rank order of potency ($1,25(\text{OH})_2\text{D}_3 > 1,24,25(\text{OH})_2\text{D}_3 > 25(\text{OH})\text{D}_3$) of the metabolites to affect accumulation of GM-CSF mRNA paralleled the affinity of the metabolites to bind to the $1,25(\text{OH})_2\text{D}_3$ cellular receptors in other tissues (31). Secondly,




Figure 2. Modulation of GM-CSF mRNA levels by $1,25(\text{OH})_2\text{D}_3$ in HTLV-1-immortalized T lymphocytes derived from a normal individual (S-LB1). (A) Dose-response experiments. S-LB1 cells were exposed for 48 h to $1,25(\text{OH})_2\text{D}_3$. Analysis was performed by Northern blot technique with 30 μg cytoplasmic RNA per lane. (B and C) Time-course experiments (Northern blot). S-LB1 cells were cultured for various durations (0.5–48 h) with $1,25(\text{OH})_2\text{D}_3$ (10^{-8} M). Each lane contains 20 μg RNA. As a control, the same samples were reprobbed with IL-2 receptor cDNA (C). Two bands were observed at 1.4 and 3.5 kb consistent with IL-2 receptor mRNA. Analysis was performed as described in Fig. 1. A single band at 0.9 kb (A and C) was detected when probed with GM-CSF cDNA.

we established a HTLV-1 immortalized T lymphocyte cell line derived from a patient with vitamin D-resistant rickets type II (Ab-VDR). Vitamin D-resistant rickets II is a heterogeneous group of syndromes characterized by a decreased or absent ability of $1,25(\text{OH})_2\text{D}_3$ to bind to its cellular receptor (1, 32). Exposure of the Ab-VDR cells to $1,25(\text{OH})_2\text{D}_3$ (10^{-8} M, 10^{-10} M) for 48 h had little effect on GM-CSF mRNA accumulation (reduction of mRNA of $\sim 15\%$ compared with control samples, as determined by densitometry) (Fig. 3 B). These results are consistent with Ab-VDR cells having undetectable $1,25(\text{OH})_2\text{D}_3$ cellular receptors, as determined by sucrose density gradient and DNA chromatography analyses (H. P. Koeffler and A. W. Norman, unpublished observations).

Influence of IL-2 on the expression of GM-CSF by S-LB1 cells. Previous studies suggested that most HTLV-1-transformed T lymphocytes do not synthesize IL-2 (33). We probed S-LB1 mRNA with a human cDNA for IL-2 (Fig. 3 C). The PHA-stimulated PBL were used as a positive control and the human promyelocytic cell line HL-60 as a negative control. A single band could be detected at 0.9 kb in PHA-activated lymphocytes consistent with IL-2 mRNA (24). However, no IL-2 mRNA could be detected in S-LB1 cells and yet cells from the same passage were regulated very sensitively by $1,25(\text{OH})_2\text{D}_3$ (Fig. 2 A).

Total RNA synthesis by S-LB1 cells in the presence of $1,25(\text{OH})_2\text{D}_3$ (^{14}C)uridine incorporation. To further examine whether $1,25(\text{OH})_2\text{D}_3$ influences total RNA synthesis in lymphocytes, we exposed S-LB1 cells ($1 \times 10^6/\text{ml}$) for 0, 6 and 24 h to $1,25(\text{OH})_2\text{D}_3$ (10^{-8} M) and measured [^{14}C]uridine incorporation into TCA precipitable counts (Table I). A 6-h exposure




Figure 3. (A) Regulation of GM-CSF mRNA by different vitamin D metabolites in S-LB1 cells (Northern blot). S-LB1 cells were exposed for 48 h to different vitamin D metabolites (10^{-8} M). (B) Regulation of GM-CSF mRNA by $1,25(\text{OH})_2\text{D}_3$ in the HTLV-1-immortalized T lymphocyte line Ab-VDR which was derived from a patient with vitamin D-resistant rickets, type II (Northern blot). S-LB1 cells (S) and Ab-VDR cells (V) were cultured for 48 h in the presence of $1,25(\text{OH})_2\text{D}_3$ (10^{-8} and 10^{-10} M). (C) Analysis of IL-2 mRNA in S-LB1 cells (Northern blot). Using an IL-2 cDNA probe, a single band could be detected from RNA of PHA-activated PBL at 0.9 kb (*Lymph.*, positive control) consistent with IL-2 mRNA; RNA from HL-60 promyelocytic leukemic cells was used as a negative control. Analysis was performed as described in Fig. 1 and Methods. Each lane in A–C contains 30 μg RNA. A single band at 0.9 kb (A and B) was detected when probed with GM-CSF cDNA.

to $1,25(\text{OH})_2\text{D}_3$ had almost no effect on RNA synthesis. A 24-h exposure to $1,25(\text{OH})_2\text{D}_3$ decreased the incorporation of [^{14}C]uridine TCA precipitable counts by $\sim 33\%$ as compared with the control sample not treated with $1,25(\text{OH})_2\text{D}_3$.

Table I. [^{14}C]Uridine Incorporation in S-LB1 Cells Exposed for Various Durations to $1,25(\text{OH})_2\text{D}_3$

Time exposed to $1,25(\text{OH})_2\text{D}_3$	Experiments		Mean percent inhibition, nos. 1 and 2
	No. 1	No. 2	
<i>h</i>	<i>cpm</i> $\times 10^4$ (%)	<i>cpm</i> $\times 10^4$ (%)	
0 (control)	9.8 \pm 0.17 (0)	1.26 \pm 0.03 (0)	0
6	9.6 \pm 0.04 (2)	1.17 \pm 0.03 (6)	4
24	6.4 \pm 0.04 (33)	0.85 \pm 0.03 (32)	33

[^{14}C]Uridine incorporation as a measurement of RNA metabolism. S-LB1 cells ($1 \times 10^6/\text{ml}$) were cultured in the presence of either ethanol control ($\leq 0.01\%$ ethanol) or $1,25(\text{OH})_2\text{D}_3$ (10^{-8} M). Results represent mean \pm SD of quadruplicate cultures of two independent experiments (Nos. 1 and 2). Numbers in parentheses denote percentage of inhibition as compared with control sample treated with no $1,25(\text{OH})_2\text{D}_3$. Analysis was performed as described in Methods.

Proliferation studies (^3H]thymidine incorporation). We measured the effect of $1,25(\text{OH})_2\text{D}_3$ (10^{-7} M) on PHA-activated PBL by measuring [^3H]thymidine incorporation. After 48 h in culture, PHA-activated PBL incorporated $11,911 \pm 4,446$ cpm/ 10^6 cells. Treatment with $1,25(\text{OH})_2\text{D}_3$ (10^{-7} M) for 48 h resulted in a statistically insignificant ($P > 0.5$) decrease of [^3H]thymidine incorporation into PBL ($8,728 \pm 2,097$ cpm/ 10^6 cells), representing a 16.7% inhibition as compared with the control samples not treated with $1,25(\text{OH})_2\text{D}_3$. The results represent the mean \pm SD for nine incubations.

Discussion

We report in the present in vitro study that $1,25(\text{OH})_2\text{D}_3$, the most active metabolite of vitamin D_3 , is a potent inhibitor of the expression of the hematopoietic growth factor GM-CSF in PHA-activated normal human peripheral blood lymphocytes (PBL). The $1,25(\text{OH})_2\text{D}_3$ regulated both protein and mRNA accumulation of GM-CSF; and this down-regulation occurred at concentrations close to those in vivo (Fig. 1). The recent reports that activated macrophages synthesize $1,25(\text{OH})_2\text{D}_3$ (12, 13) further indicate that $1,25(\text{OH})_2\text{D}_3$ might interact with GM-CSF production at a local level. Our time-response studies indicate that $1,25(\text{OH})_2\text{D}_3$ can influence GM-CSF expression by PBL also in later stages of mitogenesis (Fig. 1 E). The concentrations of $1,25(\text{OH})_2\text{D}_3$ achieving half-maximal response (ED_{50}) were 5×10^{-11} M and 5×10^{-10} M for GM-CSF mRNA levels and GM-CSF protein activity, respectively. These differences in the ED_{50} can be explained by the greater sensitivity and specificity of the RNA blot technique compared with the clonogenic assay in soft agar. In the clonogenic assay, CM from PHA-stimulated lymphocytes was used which, besides GM-CSF, also contains an admixture of other growth factors, including interleukin 3 and other lymphokines. These additional factors may have decreased both the sensitivity and specificity of the clonogenic assay. Similar to PBL, the $1,25(\text{OH})_2\text{D}_3$ sensitively inhibited mRNA accumulation of GM-CSF by the HTLV-1 immortalized T lymphocytes (S-LB1) derived from a normal individual (19) (Fig. 2 A).

The $1,25(\text{OH})_2\text{D}_3$ did not markedly affect mRNA levels for the IL-2 receptor in either the PHA-activated PBL or S-LB1 cells which constitutively produce high levels of IL-2 receptors (Figs. 1 C, 2 C). This suggests that $1,25(\text{OH})_2\text{D}_3$ does not non-specifically decrease levels of mRNA in lymphocytes. The $1,25(\text{OH})_2\text{D}_3$ inhibited total cellular RNA synthesis in S-LB1 cells as determined by incorporation of [^{14}C]uridine into TCA precipitable counts (Table I). This inhibition of total RNA, however, was much less pronounced and less rapid as compared with the decrease in GM-CSF mRNA in the same cells (4 and 52% inhibition, respectively, after exposure for 6 h to $1,25(\text{OH})_2\text{D}_3$ [Fig. 2 B, Table I]).

Several recent reports suggested that $1,25(\text{OH})_2\text{D}_3$ may be capable of immunoregulation similar to the glucocorticoids. Tsoukas et al. showed that $1,25(\text{OH})_2\text{D}_3$ inhibited the lymphocyte growth-promoting factor IL-2 by PBL (10). Studies using different vitamin D_3 metabolites suggested that the effect of $1,25(\text{OH})_2\text{D}_3$ was probably mediated by a specific receptor. Likewise, Rigby et al. demonstrated that $1,25(\text{OH})_2\text{D}_3$ was a potent inhibitor of PHA-induced lymphocyte proliferation, achieving a 70% inhibition of [^3H]thymidine incorporation after 72 h in culture (9). Another study also showed that $1,25(\text{OH})_2\text{D}_3$

inhibited the proliferation and IL-2 protein production by helper T lymphocytes (8). Similarly, 1,25(OH)₂D₃ decreased the antigen-induced proliferation and IL-2 protein synthesis by cloned Ia-restricted T cell hybridomas after 24 h in culture (11). Taken together, these studies revealed a possible immunoregulatory role for 1,25(OH)₂D₃ that has not previously been appreciated.

The 1,25(OH)₂D₃ receptors are not present in resting T lymphocytes, but do appear 24 h after mitogenic stimulation (4). The HTLV-1-immortalized T-cell lines constitutively express 1,25(OH)₂D₃ receptors. Our experiments using different vitamin D₃ metabolites suggest that the inhibition of the GM-CSF expression by 1,25(OH)₂D₃ is most likely mediated through specific cellular receptors (Fig. 3 A). The potency of these compounds to reduce mRNA levels of GM-CSF paralleled their known affinity to bind to the specific cellular receptor in other tissues (31). Furthermore, our results are in accordance with the reported dissociation constant of 3.8×10^{-10} M for 1,25(OH)₂D₃ by PHA-activated PBL (3). A more direct evidence for this assumption of a receptor-mediated mechanism relies on our study using a HTLV-1-immortalized T lymphocyte line (Ab-VDR) that was derived from a patient with vitamin D-resistant rickets type II. Exposure of Ab-VDR cells to 1,25(OH)₂D₃ resulted in only a small decrease of GM-CSF mRNA levels compared with the marked decrease in S-LB1 cells (Fig. 3 B). These results are consistent with our observation that Ab-VDR cells have undetectable 1,25(OH)₂D₃ receptors, whereas the 1,25(OH)₂D₃-sensitive S-LB1 cells display 13 fmol 1,25(OH)₂D₃ receptors/10⁶ cells, as determined by sucrose density gradient and DNA chromatography analyses (H. P. Koeffler and A. W. Norman, unpublished observations). The fact that Ab-VDR cells responded at all to 1,25(OH)₂D₃ suggests that either these cells have a low number of receptors not detectable by the present techniques or very high concentrations of 1,25(OH)₂D₃ can affect all cells independent of expression of 1,25(OH)₂D₃ receptors. Studies are currently under way to analyze the 1,25(OH)₂D₃ receptors in these cells by using a specific cDNA probe for this hormone receptor. Koren et al. recently reported that peripheral blood mononuclear cells from patients with vitamin D-resistant rickets type II do not express 1,25(OH)₂D₃ receptors, even after mitogenic stimulation (32). Moreover, proliferation of these lymphocytes could not be inhibited after a 72-h exposure to 1,25(OH)₂D₃, in contrast to the normal cells.

Because prior studies showed that 1,25(OH)₂D₃ inhibited the production of IL-2 (9, 10, 34), we questioned whether 1,25(OH)₂D₃ might mediate its inhibitory effect on the expression of GM-CSF indirectly through a down-regulation of IL-2 production. Addition of very high concentrations of IL-2 (200 ng/ml) slightly abrogated but did not reverse the inhibition of GM-CSF protein production by 1,25(OH)₂D₃ in PBL (Fig. 1 A). Furthermore, we observed that S-LB1 cells did not express IL-2 mRNA (Fig. 3 C). This T-cell line, therefore, provided an unusual tool to study our assumption of a possible IL-2-independent regulation of GM-CSF expression by 1,25(OH)₂D₃. Our dose-response and time-course experiments clearly showed that 1,25(OH)₂D₃ sensitively inhibited GM-CSF mRNA levels by S-LB1 cells in an IL-2-free system (Fig. 2, A and B). Taken together, our experiments suggest that 1,25(OH)₂D₃ can regulate independently of IL-2 the expression of a lymphokine in transformed T lymphocytes. The effect of 1,25(OH)₂D₃ on normal human PBL seems to be mostly but not totally independent from IL-2.

Our study using [³H]thymidine showed no significant inhibition of the proliferation of PHA-activated lymphocytes by 1,25(OH)₂D₃. Other investigators, however, found a marked inhibition of the lymphocyte proliferation by 1,25(OH)₂D₃, as mentioned above (8, 9, 11). This discrepancy might be explained by the fact that the PBL in the other experiments were cultured for 72 h in the presence of PHA and 1,25(OH)₂D₃, whereas in our study, [³H]thymidine incorporation was determined at 48 h of culture. Our results suggest that the inhibition of GM-CSF production by 1,25(OH)₂D₃ is not necessarily linked to its reported antiproliferative properties.

How does 1,25(OH)₂D₃ regulate the expression of GM-CSF? In the case of glucocorticoids, studies showed that mouse mammary tumor virus DNA contains regions to which the glucocorticoid-receptor complex can specifically bind. Transcription is directly stimulated by interaction of the glucocorticoid-receptor complex with DNA sequences adjacent to the promoter (reviewed in reference 35). In a parallel fashion to the glucocorticoids, the 1,25(OH)₂D₃ receptor complex might specifically bind to certain regions of DNA and inhibit the transcription of the GM-CSF gene either directly or via a transacting mechanism. Vanice et al., however, recently reported that dexamethasone regulated the expression of the alpha-1-acid glycoprotein at the posttranscriptional level (36). Preliminary experiments by us using in vitro nuclear run-on assays suggest that 1,25(OH)₂D₃ affects the stability of GM-CSF mRNA.

In summary, our study shows that 1,25(OH)₂D₃ inhibits sensitively the expression of GM-CSF by PBL and a HTLV-1 immortalized T lymphocyte line at the mRNA level. This down-regulation is mediated by a specific 1,25(OH)₂D₃ receptor and can further occur independently of IL-2. We conclude that 1,25(OH)₂D₃ might be important as a regulatory hormone in hematopoiesis.

Acknowledgments

We would like to thank Suzanne Bookstaver and Regina Simon for their excellent secretarial help, Dr. S. Clarke for generously providing the IL-2 cDNA, Dr. T. Nikaido for kindly providing the IL-2 receptor cDNA, Dr. J. Besemer for generously providing recombinant IL-2, and Dr. M. Uskokovic for kindly providing the vitamin D metabolites.

This work was supported by United States Public Health Service grants CA-26038, CA-32737, CA-33936, CA-30512, and CA-32428, the Dr. Murray Geisler Memorial Fund, the Louis Fagin Leukemia Research Foundation (Dr. Koeffler), AM-14,750-014 (Dr. Koeffler and Dr. Norman), the Deutsche Forschungsgemeinschaft (Dr. Reichel), CA-40136 (Dr. Gasson), and the Swiss and Bernese Cancer Ligues (Dr. Tobler).

References

1. Bell, N. H. 1985. Vitamin D-endocrine system. *J. Clin. Invest.* 76:1-6.
2. Manolagas, S. C., and L. J. Deftos. 1984. The vitamin D endocrine system and the hemolymphopoietic tissue. *Ann. Intern. Med.* 100:144-146.
3. Provvedini, D. M., C. D. Tsoukas, L. J. Deftos, and S. C. Manolagas. 1983. 1,25-dihydroxyvitamin D₃ receptors in human leukocytes. *Science (Wash. DC)*. 221:1181-1183.
4. Bhalla, A. K., E. P. Amento, T. L. Clemens, M. P. Holick, and S. M. Krane. 1983. Specific high-affinity receptors for 1,25-dihydroxyvitamin D₃ in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. *J. Clin. Endocrinol. & Metab.* 57:1308-1310.

5. Koeffler, H. P., T. Amatruda, N. Ikekawa, Y. Kobayashi, and H. F. DeLuca. 1984. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D₃ and its fluorinated analogs. *Cancer Res.* 44:5624-5628.
6. Mangelsdorf, D. J., H. P. Koeffler, C. A. Donaldson, J. W. Pike, and M. R. Haussler. 1984. 1,25-dihydroxyvitamin D₃-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. *J. Cell Biol.* 98:391-398.
7. Munker, R., A. W. Norman, and H. P. Koeffler. 1986. Vitamin D compounds: effects on clonal proliferation and differentiation of human myeloid cells. *J. Clin. Invest.* 78:424-430.
8. Lemire, J. M., J. S. Adams, V. Kermani-Arab, A. C. Bakke, R. Sakai, and S. C. Jordan. 1985. 1,25-dihydroxyvitamin D₃ suppresses human T helper/inducer lymphocyte activity in vitro. *J. Immunol.* 134:3032-3035.
9. Rigby, W. F. C., T. Stacy, and M. W. Fanger. 1984. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D₃ (calcitriol). *J. Clin. Invest.* 74:1451-1455.
10. Tsoukas, C. D., D. M. Provvedini, and S. C. Manolagas. 1984. 1,25-dihydroxyvitamin D₃: a novel immunoregulatory hormone. *Science (Wash. DC)*. 224:1438-1440.
11. Bhalla, A. K., E. P. Amento, B. Serog, and L. H. Glimcher. 1984. 1,25-dihydroxyvitamin D₃ inhibits antigen-induced T cell activation. *J. Immunol.* 113:1748-1754.
12. Adams, J. S., and M. A. Gacad. 1985. Characterization of 1 α -hydroxylation of vitamin D₃ sterols by cultured alveolar macrophages from patients with sarcoidosis. *J. Exp. Med.* 161:755-765.
13. Koeffler, H. P., H. Reichel, J. E. Bishop, and A. W. Norman. 1985. γ -Interferon stimulates production of 1,25-dihydroxyvitamin D₃ by normal human macrophage. *Biochem. Biophys. Res. Commun.* 127:596-603.
14. Cantrel, M. A., D. Anderson, D. P. Cerretti, V. Price, K. McKereghan, R. J. Tushinski, D. Y. Mochizuki, A. Larsen, K. Grabstein, S. Gillis, and D. Cosman. 1985. Cloning, sequence, and expression of a human granulocyte-macrophage colony-stimulating factor. *Proc. Natl. Acad. Sci. USA.* 82:6250-6254.
15. Wong, G. G., J. A. S. Witek, P. A. Temple, K. M. Wilkens, A. C. Leary, D. P. Luxenberg, S. S. Jones, E. L. Brown, R. M. Kay, E. C. Orr, C. H. Shoemaker, D. W. Golde, R. J. Kaufman, R. M. Hewick, E. A. Wang, and S. C. Clark. 1985. Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. *Science (Wash. DC)*. 228:810-815.
16. Tomonaga, M., D. W. Golde, and J. C. Gasson. 1986. Biosynthetic (recombinant) human granulocyte-macrophage colony-stimulating factor: effect on normal bone marrow and leukemic cell lines. *Blood.* 67:31-36.
17. Sieff, C. A., S. G. Emerson, R. E. Donahue, D. G. Nathan, E. A. Wang, G. G. Wong, and S. C. Clark. 1985. Recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin. *Science (Wash. DC)*. 230:1171-1173.
18. Gasson, J. C., R. H. Weissbart, S. E. Kaufman, S. C. Clark, R. M. Hewick, G. G. Wong, and D. W. Golde. 1984. Purified human granulocyte-macrophage colony-stimulating factor: direct action on neutrophils. *Science (Wash. DC)*. 226:1339-1342.
19. Weissbart, R. H., D. W. Golde, S. C. Clark, G. G. Wong, and J. C. Gasson. 1985. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. *Nature.* 314:361-363.
20. Koeffler, H. P., I. S. Y. Chen, and D. W. Golde. 1984. Characterization of a novel HTLV-infected cell line. *Blood.* 64:482-490.
21. Colline, S. J., R. C. Gallo, and R. E. Gallagher. 1977. Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. *Nature (Lond.)*. 270:347-349.
22. Koeffler, H. P., and D. W. Golde. 1978. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. *Science (Wash. DC)*. 200:1153-1154.
23. Golde, D. W., S. G. Quan, and M. J. Cline. 1978. Human T lymphocyte cell line producing colony-stimulating activity. *Blood.* 52:1068-1072.
24. Clark, S., S. K. Arya, F. Wong-Staal, M. Matsumoto-Kobayashi, R. M. Kay, R. J. Kaufman, E. L. Brown, C. Shoemaker, T. Copeland, S. Oroszlan, K. Smith, M. G. Sarngadharan, S. G. Lindner, and R. C. Gallo. 1984. Human T-cell growth factor: partial amino acid sequence, cDNA cloning, and organization and expression in normal and leukemic cells. *Proc. Natl. Acad. Sci. USA.* 81:2543-2547.
25. Nikaïdo, T., A. Shimizu, N. Ishida, H. Sabe, K. Teshigawara, M. Maeda, T. Uchiyama, J. Yodoi, and T. Honjo. 1984. Molecular cloning of cDNA encoding human interleukin-2 receptor. *Nature (Lond.)*. 311:631-635.
26. Feinberg, A. P., and B. Vogelstein. 1983. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. *Anal. Biochem.* 132:6-13.
27. Maniatis, T., E. P. Fritsch, and J. Sambrook. 1982. *Molecular Cloning: a Laboratory Manual*. Cold Spring Harbor, NY. 109-112.
28. Clemens, M. J. 1984. Purification of eukaryotic mRNA. In *Transcription and Translation*. B. D. Hames and S. J. Higgins, editors. IRL Press, Washington. 211-220.
29. Uchiyama, T., T. Hori, M. Tsudo, Y. Wano, H. Umadome, S. Tamori, J. Yodoi, M. Maeda, H. Sawami, and H. Uchino. 1985. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. *J. Clin. Invest.* 76:446-453.
30. Waldmann, T. A. 1986. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. *Science (Wash. DC)*. 232:727-732.
31. Proscal, D. A., W. H. Okamura, and A. W. Norman. 1976. Vitamin D, its metabolites and analogs: a review of the structural requirements for biological activity. *Am. J. Clin. Nutr.* 29:1271-1282.
32. Koren, R., A. Ravid, U. A. Liberman, Z. Hochberg, Y. Weisman, and A. Novogrodsky. 1985. Defective binding and function of 1,25-dihydroxyvitamin D₃ receptors in peripheral mononuclear cells of patients with end-organ resistance to 1,25-dihydroxyvitamin D. *J. Clin. Invest.* 76:2012-2015.
33. Arya, S. K., F. Wong-Staal, and R. C. Gallo. 1984. T-cell growth factor gene: lack of expression in human T-cell leukemia-lymphoma virus-infected cells. *Science (Wash. DC)*. 223:1086-1087.
34. Lemire, J. M., J. S. Adams, R. Sakai, and S. C. Jordan. 1984. 1 α ,25-dihydroxyvitamin D₃ suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. *J. Clin. Invest.* 74:657-661.
35. Ringold, G. M. 1983. Regulation of mouse mammary tumor virus gene expression by glucocorticoid hormones. *Curr. Top. Microbiol. Immunol.* 106:79-103.
36. Vanice, J. L., J. M. Taylor, and G. M. Ringold. 1984. Glucocorticoid-mediated induction of alpha 1-acid glycoprotein: evidence for hormone-regulated processing. *Proc. Natl. Acad. Sci. USA.* 81:4241-4245.